港股異動丨業務合併!微創醫療升近7%,心通醫療升超20%
港股市場微創醫療(0853.HK)一度升近7%,報9.24港元,心通醫療-B(2160.HK)一度升超20%報1.34港元。消息面上,微創醫療公佈,董事會正考慮一項有關建議策略,重組集團心律管理(CRM)業務的不具約束力建議。待與有興趣人士進一步磋商,CRM業務將與微創心通的業務合併。兩項業務合併有助集團建立心臟病產品平台,提供多元化產品及產品管線,藉此將提升集團的全球市場開發能力,從而使經合併業務在全球範圍內,進一步加強其在各自分部的定位。可進一步共享及統籌全球市場資源,產生協同效應,擴大現有合作的廣度與深度,及有助集團在全球市場建立更強大的據點及市場影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.